Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

INSYS Therapeutics logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INSY Stock News Headlines

Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Aldeyra Therapeutics, Inc. (ALDX)
See More Headlines

INSY Stock Analysis - Frequently Asked Questions

INSYS Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.33. The business's quarterly revenue was down 68.1% on a year-over-year basis.

Shares of INSYS Therapeutics split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
5/10/2019
Today
5/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-124,510,000.00
Net Margins
-346.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$82.08 million
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INSY) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners